Search results for "Cytoreduction"

showing 6 items of 26 documents

Peritoneal carcinosis of ovarian origin

2010

Epithelial ovarian cancer (EOC) is the second most common genital malignancy in women and is the most lethal gynecological malignancy, with an estimated five-year survival rate of 39%. Despite efforts to develop an effective ovarian cancer screening method, 60% of patients still present with advanced disease. Comprehensive management using surgical cytoreduction to decrease the tumor load to a minimum, and intraperitoneal chemotherapy to eliminate microscopic disease on peritoneal surface, has the potential to greatly improve quality of life and to have an impact on survival in ovarian cancer patients. Despite achieving clinical remission after completion of initial treatment, most patients…

Oncologymedicine.medical_specialtyendocrine system diseasesbusiness.industryPeritoneal carcinosisGastroenterologyDrug resistancemedicine.diseaseMalignancySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsSurgeryCytoreductionOvarian cancer Intraperitoneal hyperthermic chemotherapyOncologyQuality of lifePeritoneal carcinosiInternal medicinemedicineSex organTopic HighlightOvarian cancerbusinessSurvival rateTumor LoadWorld Journal of Gastrointestinal Oncology
researchProduct

Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?

2015

BACKGROUND: The aim of the present study was to evaluate the efficacy of tertiary and quaternary cytoreduction in recurrent ovarian cancer patients. PATIENTS AND METHODS:Between January 1997 and December 2014, 53 patients were submitted to cytoreductive surgery for second and third ovarian cancer recurrence at our Unit. RESULTS:Median age at first diagnosis was 48 years (range=20-69). Forty-six patients (86.8%) underwent tertiary cytoreduction. At the time of surgery, isolated and diffuse disease was observed in 48 (90.6%) and 5 (9.4%) patients, respectively. Complete and optimal cytoreduction was obtained in 41 (77.5%) and in 1 (1.9%) patients, respectively. We did not observe any statisti…

Ovarian NeoplasmsAdultReoperationCytoreduction Surgical ProcedureMedicine (all)Ovarian NeoplasmTCR QCR cytoreductionRecurrent ovarian cancer; quaternary cytoreduction; tertiary cytoreduction; Adult; Aged; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Recurrence; Local; Ovarian Neoplasms; Reoperation; Survival Analysis; Young Adultquaternary cytoreductionCytoreduction Surgical ProceduresMiddle AgedSurvival AnalysisYoung Adultovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAtertiary cytoreductionHumansFemaleSurvival AnalysiRecurrent ovarian cancerNeoplasm Recurrence Localquaternary cytoreduction; Recurrent ovarian cancer; tertiary cytoreduction; Medicine (all)AgedHuman
researchProduct

Role of Cytoreductive surgery in recurrent ovarian cancer

2010

Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60% of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness …

Secondary cytoreductionOncologymedicine.medical_specialtyendocrine system diseaseshypertermic intraoperative peritoneal chemotherapyGynecologic oncology; HIPEC; Hyperthermic intraoperative peritoneal chemotherapy; Recurrent ovarian cancer; Secondary cytoreductionGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreductionDiseaseGynecologic oncologyHyperthermic intraoperative peritoneal chemotherapyInternal medicinemedicinePharmacology (medical)Cause of deathHIPECbusiness.industrySystemic chemotherapyCombination chemotherapyGeneral Medicinemedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaGynecologic oncologyGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreduction; hypertermic intraoperative peritoneal chemotherapyRecurrent Ovarian CancerRecurrent ovarian cancerbusinessOvarian cancerCytoreductive surgery
researchProduct

Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience

2014

Background: Optimally, secondary cytoreduction is acknowledged as a valid option in terms of oncologic outcome for patients with platinum-sensitive recurrent ovarian cancer. In cases of localized relapse, a laparoscopic approach has been attempted at various institutions, but studies on its role for this subset of patients still are limited. This report describes the authors' experience using laparoscopic secondary cytoreduction for patients with localized recurrent ovarian cancer. The results from a retrospective analysis of a prospective case series are reported. Methods: Between October 2011 and May 2013, 29 patients with localized recurrent ovarian cancer were selected for a laparoscopi…

Secondary cytoreductionmedicine.medical_treatmentTissue AdhesionsPostoperative ComplicationsLaparotomyLaparoscopyOvarian Neoplasmsmedicine.diagnostic_testMedicine (all)Middle Agedovarian cancerChemotherapy AdjuvantLymphatic MetastasisFemaleAdult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy; Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Laparoscopy; Laparotomy; Length of Stay; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Monitoring; Intraoperative; Neoplasm Recurrence; Local; Neoplasm Staging; Operative Time; Ovarian Neoplasms; Postoperative Complications; Retrospective Studies; Tissue AdhesionsAdultmedicine.medical_specialtyRecurrent ovarian cancer; Laparoscopy; Secondary cytoreductionOperative TimeAntineoplastic AgentsDisease-Free SurvivalLaparoscopicMonitoring IntraoperativeInternal medicineCarcinomamedicineHumansAgedNeoplasm StagingRetrospective StudiesLaparotomybusiness.industryGeneral surgeryCarcinomaRetrospective cohort studyLength of StayHepatologymedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIARecurrent Ovarian CancerLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalRecurrent ovarian cancerOvarian cancerbusinessFollow-Up StudiesAbdominal surgery
researchProduct

Minimally invasive gastrectomy: time to change practice?

2020

medicine.medical_specialtyHepatologybusiness.industryGeneral surgerymedicine.medical_treatmentDissectionGastroenterologyCytoreduction Surgical ProceduresGastrectomyStomach NeoplasmsMedicineHumansGastrectomyLaparoscopybusinessThe lancet. Gastroenterologyhepatology
researchProduct

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct